Oculis (OCS) Competitors $22.91 +0.56 (+2.51%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$23.20 +0.29 (+1.27%) As of 01/31/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OCS vs. PTCT, CRNX, RYTM, ACLX, DNLI, IMVT, TWST, XENE, ACAD, and VCELShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include PTC Therapeutics (PTCT), Crinetics Pharmaceuticals (CRNX), Rhythm Pharmaceuticals (RYTM), Arcellx (ACLX), Denali Therapeutics (DNLI), Immunovant (IMVT), Twist Bioscience (TWST), Xenon Pharmaceuticals (XENE), ACADIA Pharmaceuticals (ACAD), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Oculis vs. PTC Therapeutics Crinetics Pharmaceuticals Rhythm Pharmaceuticals Arcellx Denali Therapeutics Immunovant Twist Bioscience Xenon Pharmaceuticals ACADIA Pharmaceuticals Vericel Oculis (NASDAQ:OCS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment. Do analysts recommend OCS or PTCT? Oculis presently has a consensus target price of $28.80, indicating a potential upside of 25.71%. PTC Therapeutics has a consensus target price of $55.00, indicating a potential upside of 19.88%. Given Oculis' stronger consensus rating and higher probable upside, research analysts plainly believe Oculis is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00PTC Therapeutics 3 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.47 Which has preferable earnings & valuation, OCS or PTCT? Oculis has higher earnings, but lower revenue than PTC Therapeutics. Oculis is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$980K946.88-$98.92M-$1.93-11.87PTC Therapeutics$937.82M3.77-$626.60M-$5.94-7.72 Do insiders and institutionals have more ownership in OCS or PTCT? 22.3% of Oculis shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer OCS or PTCT? In the previous week, PTC Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 4 mentions for PTC Therapeutics and 3 mentions for Oculis. Oculis' average media sentiment score of 0.63 beat PTC Therapeutics' score of 0.61 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, OCS or PTCT? Oculis has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Is OCS or PTCT more profitable? PTC Therapeutics has a net margin of -50.32% compared to Oculis' net margin of -8,043.28%. PTC Therapeutics' return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,043.28% -71.31% -56.85% PTC Therapeutics -50.32%N/A -16.44% Does the MarketBeat Community favor OCS or PTCT? PTC Therapeutics received 534 more outperform votes than Oculis when rated by MarketBeat users. However, 90.32% of users gave Oculis an outperform vote while only 61.89% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformOculisOutperform Votes2890.32% Underperform Votes39.68%PTC TherapeuticsOutperform Votes56261.89% Underperform Votes34638.11% SummaryPTC Therapeutics beats Oculis on 10 of the 18 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$927.95M$6.88B$5.58B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E Ratio-11.874.5158.9914.21Price / Sales946.88320.231,258.0383.19Price / CashN/A73.5045.9637.70Price / Book7.985.275.124.71Net Income-$98.92M$136.98M$111.17M$224.24M7 Day Performance1.78%-0.59%2.37%-0.17%1 Month Performance34.76%0.18%3.19%0.60%1 Year Performance81.25%7.68%24.69%20.43% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.8468 of 5 stars$22.91+2.5%$28.80+25.7%+74.1%$927.95M$980,000.00-11.872Short Interest ↑Positive NewsPTCTPTC Therapeutics3.6659 of 5 stars$46.07-0.8%$55.00+19.4%+75.9%$3.55B$937.82M-7.761,410CRNXCrinetics Pharmaceuticals3.7575 of 5 stars$38.21-1.5%$72.64+90.1%+10.5%$3.54B$4.01M-10.24210Short Interest ↑RYTMRhythm Pharmaceuticals3.8255 of 5 stars$56.42-2.4%$68.09+20.7%+34.7%$3.47B$77.43M-13.03140ACLXArcellx2.9633 of 5 stars$62.93-0.1%$105.93+68.3%+10.2%$3.40B$155.82M-88.6380Short Interest ↑DNLIDenali Therapeutics4.4729 of 5 stars$23.19+4.4%$38.91+67.8%+45.5%$3.34B$330.53M-8.40430Analyst ForecastShort Interest ↑Analyst RevisionIMVTImmunovant2.7002 of 5 stars$22.40-2.8%$47.00+109.8%-40.3%$3.29BN/A-10.09120Analyst UpgradeTWSTTwist Bioscience2.8055 of 5 stars$52.23-3.4%$51.90-0.6%+61.6%$3.10B$312.97M-14.51990XENEXenon Pharmaceuticals2.6228 of 5 stars$40.11+0.4%$56.00+39.6%-11.6%$3.06B$9.43M-14.22210Analyst RevisionACADACADIA Pharmaceuticals4.0104 of 5 stars$18.27-2.1%$25.25+38.2%-28.0%$3.04B$726.44M23.42510Short Interest ↑Analyst RevisionNews CoverageVCELVericel2.5215 of 5 stars$59.72+4.0%$62.14+4.1%+36.2%$2.95B$197.52M995.50300Insider Trade Related Companies and Tools Related Companies PTCT Competitors CRNX Competitors RYTM Competitors ACLX Competitors DNLI Competitors IMVT Competitors TWST Competitors XENE Competitors ACAD Competitors VCEL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCS) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDo this Before Elon’s Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
